Drug Type Autologous CAR-T |
Synonyms Anti-BCMA CAR-T Cell Therapy - Novartis Pharmaceuticals, a B-cell maturation antigen (BCMA)-directed, genetically engineered T cell immunotherapy product derived from an autologous leukapheresis + [1] |
Target |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapse multiple myeloma | Phase 2 | GB | 03 Mar 2022 | |
Relapse multiple myeloma | Phase 2 | US | 03 Mar 2022 | |
Relapse multiple myeloma | Phase 2 | IT | 03 Mar 2022 | |
Relapse multiple myeloma | Phase 2 | CA | 03 Mar 2022 | |
Relapse multiple myeloma | Phase 2 | FR | 03 Mar 2022 | |
Relapse multiple myeloma | Phase 2 | GR | 03 Mar 2022 | |
Relapse multiple myeloma | Phase 2 | ES | 03 Mar 2022 | |
Relapse multiple myeloma | Phase 2 | BR | 03 Mar 2022 | |
Relapse multiple myeloma | Phase 2 | JP | 03 Mar 2022 | |
Relapse multiple myeloma | Phase 2 | DE | 03 Mar 2022 |
NCT04318327 (ASCO2023) Manual | Phase 1 | Relapse multiple myeloma Third line | 46 | (fthhqawsgg) = Dose limiting toxicities were experienced by 13% of pts and included gr 4 neutropenia, gr 4 lipase increase, gr 3 serum amylase increase, gr 3 neurotoxicity, gr 3 transaminitis, and gr 3 ejection fraction reduction. tcamjzlapy (pbugjrhnuc ) View more | Positive | 26 May 2023 | |
NCT04318327 (EHA2022) Manual | Phase 1 | 22 | (ailgbnrvlu) = ofmdcftllx eqyiqjqhsc (farvmkdxgz ) View more | Positive | 12 May 2022 | ||
NCT04318327 (ASH2021) Manual | Phase 1 | Relapse multiple myeloma Last line | 7 | PHE-885 | (prqtsvnmmx) = ifkmksdjtz ttmxiintnk (anjgvoeiua ) View more | Positive | 05 Nov 2021 |